» Articles » PMID: 20138958

Iodine Induces Apoptosis Via Regulating MAPKs-related P53, P21, and Bcl-xL in Thyroid Cancer Cells

Overview
Date 2010 Feb 9
PMID 20138958
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common endocrine malignancy and exhibits the full range of malignant behaviors from the relatively indolent occult differentiated thyroid cancer to uniformly aggressive and lethal anaplastic thyroid cancer. Iodine is a well known key element in thyroid normal function maintenance and thyroid cancer development. However, the effects induced by iodine and the molecular mechanisms involved remain poorly understood in thyroid cancer. We investigated the apoptotic effect of iodine on three different subtypes of thyroid cancer cells. We observed that apoptosis induced by iodine was mitochondrial-mediated. Iodine treatment decreased the level of mutant p53 including the R273H mutant that possesses anti-apoptotic features, but increased the p21 level. Surprisingly, high doses of iodine promoted instead of suppressed the expression of anti-apoptotic protein Bcl-xL expression. Moreover, iodine transiently activated the subfamily members of mitogen activated protein kinases (MAPKs) (ERK1/2, p38 and JNK1/2) which contribute to modulate p53, p21 and Bcl-xL expression. The further results showed the three subfamily members of MAPKs all worked as anti-apoptotic factors. Collectively, iodine-induced apoptotic pathway is involved in the activation of MAPKs-related p21, Bcl-xL and mutant p53 regulation. The findings provide solid molecular evidence to explain the potential pathway for iodine to influence thyroid cancer development. It may also reveal some novel molecular targets for the treatment of thyroid cancer.

Citing Articles

Biodegradable copper-iodide clusters modulate mitochondrial function and suppress tumor growth under ultralow-dose X-ray irradiation.

Ma X, Lin N, Yang Q, Liu P, Ding H, Xu M Nat Commun. 2024; 15(1):8092.

PMID: 39285181 PMC: 11405764. DOI: 10.1038/s41467-024-52278-6.


Metal nanoparticles for cancer therapy: Precision targeting of DNA damage.

Chen Q, Fang C, Xia F, Wang Q, Li F, Ling D Acta Pharm Sin B. 2024; 14(3):1132-1149.

PMID: 38486992 PMC: 10934341. DOI: 10.1016/j.apsb.2023.08.031.


USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway.

Sun J, Xiang Q, Ding D, Yan N J Bioenerg Biomembr. 2023; 55(6):457-466.

PMID: 37919637 PMC: 10682060. DOI: 10.1007/s10863-023-09986-3.


The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.

Koronowicz A, Drozdowska M, Wielgos B, Piasna-Slupecka E, Domagala D, Dulinska-Litewka J PLoS One. 2018; 13(2):e0192860.

PMID: 29444163 PMC: 5812662. DOI: 10.1371/journal.pone.0192860.


Iodine stimulates estrogen receptor singling and its systemic level is increased in surgical patients due to topical absorption.

He S, Wang B, Lu X, Miao S, Yang F, Zava T Oncotarget. 2018; 9(1):375-384.

PMID: 29416620 PMC: 5787473. DOI: 10.18632/oncotarget.20633.